Sentiment Trading

Incannex Healthcare’s stock price surged by over 800% due to positive developments in its clinical trial for IHL-42X, a treatment for obstructive sleep apnea, fueling investor optimism and market interest in the company’s pipeline.

Incannex Healthcare Inc. has successfully completed Phase 2 enrollment in its RePOSA Phase 2/3 trial, marking a significant milestone in the development of its oral treatment for obstructive sleep apnoea.

Incannex Healthcare Inc. is a clinical-stage pharmaceutical company pioneering medicinal cannabis and psychedelic therapies for various health conditions, with potential to revolutionize treatment paradigms.